The Endpoints 100: What impact has Trump 2.0 had on biotech? And what comes next?

Tuesday, May 20, 2025 ● 12:00 PM ET

Biotech executives are navigating regulatory upheaval and global trade disruptions. How will biopharma insulate itself from the fallout? Our latest Endpoints 100 survey takes the pulse of the industry at this pivotal moment.

Join Endpoints News Editor-in-Chief John Carroll and top industry voices for an exclusive panel unpacking the critical insights from our H1 2025 survey. As the FDA undergoes its most significant reorganization in decades and new tariffs reshape global supply chains, hear how industry leaders are adapting — in real time.

Get beyond the headlines and hear directly from the decision-makers shaping biopharma’s future. Join us.